background
caus
agent
declar
global
pandem
treatment
guidelin
vari
countri
yet
approv
therapeut
includ
search
term
includ
combin
covid
glucocorticoid
convalesc
plasma
antivir
antibacteri
restrict
type
studi
design
elig
inclus
march
th
initi
manuscript
identifi
fortyon
studi
includ
consist
clinic
trial
case
report
case
seri
retrospect
prospect
observ
studi
thirtysix
studi
conduct
china
commonli
report
medicin
systemat
review
corticosteroid
follow
lopinavir
oseltamivir
sever
acut
respiratori
syndrom
coronaviru
caus
coronaviru
diseas
covid
declar
global
pandem
world
health
organ
discov
decemb
wuhan
citi
capit
hubei
provinc
china
origin
viru
unknown
initi
newli
diagnos
case
link
huanan
seafood
wholesal
market
peopl
buy
wild
anim
bat
phylogenet
similar
sarscov
merscov
viru
identifi
novel
envelop
rna
betacoronaviru
name
sever
acut
respiratori
syndrom
coronaviru
one
characterist
highli
contagi
mani
countri
affect
includ
china
countri
less
three
month
despit
china
reach
confirm
case
death
countri
report
one
new
domest
case
march
th
date
total
worldwid
confirm
case
death
although
protect
measur
implement
china
isol
confirm
suspect
case
reduc
spread
viru
need
effect
treatment
imper
stop
outbreak
reduc
morbid
mortal
sinc
onset
outbreak
research
propos
mani
agent
could
efficaci
differ
antivir
agent
includ
latest
guidelin
nation
health
commiss
nhc
includ
interferon
lopinavirritonavir
chloroquin
phosphat
ribavirin
arbidol
angiotensin
receptor
blocker
losartan
anoth
suggest
treat
treatment
guidelin
vari
countri
guidelin
gener
manag
symptom
advis
cautiou
paediatr
patient
pregnant
patient
underli
comorbid
approv
treatment
care
advis
give
support
manag
accord
patient
need
antipyret
fever
oxygen
therapi
patient
respiratori
distress
moreov
recommend
sever
case
give
empir
antimicrobi
therapi
implement
mechan
ventil
depend
patient
clinic
condit
asian
guidelin
easi
interpret
yet
translat
english
japanes
guidelin
treatment
protocol
across
countri
similar
use
hydroxychloroquin
chloroquin
phosphat
remedesivir
lopinavirritonavir
slight
differ
countri
treatment
guidelin
repres
tabl
light
limit
scarc
evid
around
therapeut
literatur
review
aim
retrospect
evalu
therapeut
manag
given
patient
sinc
emerg
viru
systemat
review
protocol
develop
base
prismap
prisma
statement
articl
review
select
electron
databas
embas
medlin
googl
scholar
readili
access
peerreview
full
articl
english
publish
decemb
st
march
th
includ
search
term
includ
combin
glucocorticoid
chloroquin
convalesc
plasma
antivir
antibacteri
oseltamivir
hydroxychloroquin
chloroquin
phosphat
monoclon
antibodi
restrict
type
studi
design
elig
inclus
howev
like
quantit
rct
studi
focu
review
therapeut
use
manag
patient
primari
outcom
evid
therapeut
use
manag
patient
clinic
practic
irrespect
patient
characterist
set
outcom
measur
discuss
common
report
medicin
review
clinic
outcom
therapeut
treatment
recoveri
mortal
patient
secondari
outcom
advers
event
associ
treatment
duplic
articl
remov
titl
independ
screen
review
abstract
follow
full
articl
review
doubt
remain
inclus
exclus
record
follow
prisma
guidelin
present
form
prisma
flow
diagram
detail
reason
record
exclus
critic
apprais
checklist
appropri
studi
design
appli
check
second
team
member
bia
qualiti
issu
identifi
consid
prior
quantit
metaanalysi
metanarr
casp
apprais
checklist
tool
use
qualiti
assess
data
extract
tool
design
captur
focu
interest
popul
geograph
locat
methodolog
specif
mention
therapeut
treatment
advers
event
key
find
research
ethic
approv
requir
review
exist
peer
review
literatur
march
th
initi
manuscript
identifi
articl
inclus
exclus
report
follow
prisma
guidelin
present
form
prisma
flow
diagram
figur
reason
exclus
record
tabl
follow
duplic
remov
record
exclud
exclud
due
languag
chines
dutch
vietnames
italian
russian
portugues
iranian
german
ten
articl
exclud
reason
includ
incomplet
irrelev
articl
consensu
final
inclus
studi
negoti
without
need
third
review
present
tabl
fortyon
studi
includ
clinic
trial
case
report
case
seri
retrospect
prospect
observ
studi
thirtysix
studi
conduct
china
one
korea
usa
franc
singapor
macau
total
number
patient
report
studi
mean
age
year
studi
age
specifi
studi
commonli
report
therapeut
systemat
review
antiinflammatori
medic
corticosteroid
differ
name
product
characterist
corticosteroid
methylprednisolon
dexamethason
follow
antivir
hiv
medic
lopinavir
combin
lopinavirritonavir
alon
follow
oseltamivir
arbidol
hydrochlorid
term
antibacteri
medicin
moxifloxacin
tigecyclin
report
convalesc
plasma
therapi
report
one
multi
center
retrospect
observ
studi
six
patient
outcom
measur
record
vari
patient
discharg
recoveri
ongo
hospit
mortal
avail
data
concern
issu
shown
tabl
first
date
review
relat
therapeut
use
patient
systemat
manner
march
th
sinc
emerg
elig
research
articl
therapeut
found
includ
current
systemat
review
three
clinic
trial
either
case
report
case
seri
prospect
retrospect
observ
studi
system
corticosteroid
differ
name
formul
commonli
report
medic
follow
antivir
lopinavir
oseltamivir
arbidol
hydrochlorid
convalesc
plasma
therapi
mention
one
multicent
retrospect
observ
studi
administ
six
patient
although
qualiti
assess
appli
includ
research
articl
insuffici
evid
articl
identifi
review
conduct
metaanalysi
subgroup
analysi
adult
children
differ
formul
dosag
durat
appropri
report
articl
review
low
qualiti
design
outcom
studi
incomplet
inconsist
henc
difficult
interpret
therapeut
term
efficaci
safeti
despit
limit
first
systemat
review
link
therapeut
use
patient
furthermor
review
provid
uptod
insight
current
therapeut
guidelin
manag
patient
report
medicin
review
alreadi
place
usa
saudi
arabia
europ
egypt
tabl
corticosteroid
commonli
report
use
medicin
review
howev
recommend
mention
guidelin
world
health
organ
unit
state
center
diseas
control
prevent
cdc
absenc
conclus
scientif
evid
recommend
corticosteroid
routin
use
patient
treatment
viral
pneumonia
acut
respiratori
distress
syndrom
ard
unless
indic
condit
asthma
chronic
obstruct
pulmonari
diseas
copd
exacerb
septic
shock
care
use
corticosteroid
lowtomoder
dose
short
cours
advis
hyperglycemia
hypernatremia
hypokalemia
common
advers
effect
associ
corticosteroid
use
routin
monitor
lopinavirritonavir
avail
brand
name
kaletra
second
report
medicin
review
rct
cao
b
et
al
report
neg
outcom
hiv
treatment
patient
tabl
benefit
observ
lopinavirritonavir
treatment
beyond
standard
care
studi
patient
receiv
intervent
die
howev
limit
observ
studi
includ
lack
blind
rct
solidar
trial
ongo
determin
efficaci
lopinavirritonavir
patient
oseltamivir
third
report
therapeut
review
sold
brand
name
tamiflu
use
treat
influenza
influenza
b
oseltamivir
recommend
peopl
high
risk
infect
prevent
pandem
influenza
guan
w
colleagu
retrospect
observ
studi
report
use
oseltamivir
patient
howev
studi
abl
provid
solid
data
effect
oseltamivir
prevent
treatment
patient
studi
limit
includ
incomplet
document
patient
data
recal
bia
arbidol
hydrochlorid
fourth
report
medicin
review
broadspectrum
inhibitor
influenza
b
viru
parainfluenza
viru
virus
includ
hepat
c
viru
use
russia
china
yet
approv
use
countri
howev
conclus
evid
efficaci
report
review
report
togeth
favipiravir
approv
recent
treatment
novel
influenza
februari
th
china
chloroquin
phosphat
hydroxychloroquin
report
review
show
favor
outcom
recoveri
patient
mechan
action
virus
two
medicin
like
effect
chloroquin
use
long
time
treat
malaria
show
posit
outcom
patient
furthermor
hydroxychloroquin
show
signific
effect
kill
intracellar
pathogen
coxiella
burnetii
agent
q
fever
french
open
label
nonrandom
clinic
trial
promis
first
clinic
trial
medic
patient
effect
hydroxychloroquin
signific
show
reduct
viral
load
compar
control
group
moreov
effect
hydroxychloroquin
significantli
potent
azithromycin
ad
patient
accord
clinic
need
howev
clinic
followup
occurr
advers
effect
discuss
paper
work
done
medicin
aim
reduc
morbid
mortal
although
two
medicin
shown
promis
activ
risk
arrhythmia
associ
administr
therefor
caution
requir
use
higher
cumul
dosag
recommend
use
suspectedconfirm
restrict
hospit
patient
march
th
us
food
drug
administr
us
fda
issu
emerg
use
author
eua
chloroquin
hydroxychloroquin
treat
patient
hospit
convalesc
plasma
treatment
mention
review
multicentr
cohort
research
trial
critic
ill
patient
admit
icu
wuhan
find
show
convalesc
plasma
administ
six
patient
transfus
reaction
occur
howev
studi
could
provid
adequ
inform
efficaci
convalesc
plasma
due
limit
sampl
size
lack
random
control
group
fact
convalesc
plasma
therapi
could
promis
method
treatment
patient
recent
case
seri
report
china
show
five
critic
ill
patient
laboratori
confirm
ard
improv
receiv
plasma
transfus
bodi
temperatur
normal
within
day
patient
viral
load
becam
undetect
within
day
patient
discharg
hospit
stabl
condit
day
post
transfus
march
th
us
fda
approv
convalesc
plasma
treatment
investig
use
tradit
investig
new
drug
applic
ind
regulatori
pathway
elig
patient
confirm
sever
immedi
lifethreaten
condit
respiratori
failur
septic
shock
andor
multipl
organ
dysfunct
failur
notabl
potenti
risk
ethic
issu
associ
use
includ
increas
thrombot
event
risk
lack
high
qualiti
research
particular
area
select
donor
high
neutral
antibodi
titer
first
date
systemat
review
therapeut
use
patient
research
articl
therapeut
found
elig
includ
conduct
china
three
clinic
trial
antiinflammatori
medic
corticosteroid
found
mention
wide
use
medicin
studi
despit
safeti
alert
issu
cdc
follow
antivir
medic
lopinavir
oseltamivir
arbidol
hydrochlorid
although
research
warrant
amount
evid
increas
studi
present
current
pictur
treatment
modal
use
efficaci
safeti
profil
treatment
need
character
futur
studi
two
recipi
selflimit
skin
erupt
studi
address
focus
issu
random
done
intent
treat
analysi
popul
enter
studi
properli
account
conclus
blind
done
group
enter
studi
similar
togeth
treat
equal
primari
outcom
clearli
specifi
one
patient
stop
treatment
postinclus
nausea
clinic
followup
occurr
sideeffect
discuss
paper
huang
inform
visit
wwwprismastatementorg
